UCB, Others Sue 15 Generics Makers For Violating Vimpat Drug Patent
This article was originally published in PharmAsia News
Glenmark, Ranbaxy Laboratories, Sun Pharma and other India drug makers are among 15 sued in a U.S. federal court for violating the patent of the epilepsy drug Vimpat (lacosamide) licensed to UCB.
You may also be interested in...
Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in November 2022. Data provided by Citeline's Biomedtracker.
Recent executive changes in the industry include C-suite changes at Solid Biosciences and Merck & Co. Meanwhile, new directors were appointed at Allergy Therapeutics and Synairgen.
The US firm’s adagrasib regimen has failed to differentiate itself from Keytruda plus chemotherapy in two early mNSCLC trials but Mirati is nonetheless forging ahead with pivotal development, albeit with strictly defined populations.